Increased levels of calreticulin have been reported in hepatocellular, colon, prostate and bladder carcinomas and as well as in radioresistant squamous carcinoma (Ramsamooj et al, 1995; Alaiya et al, 2000; Yoon et al, 2000; Brunagel et al, 2003; Iwaki et al, 2004). Here, CALR is linked to urinary bladder carcinoma.